Acquisition of human papillomavirus (HPV) results in an infection of variable duration which
may or may not be associated with clinically apparent lesions. Lesions caused by skintropic …

Cervical cancer is the second leading cause of cancer in women worldwide. Human
papillomavirus (HPV) is responsible for all cases of cervical cancer. Commercial …

Eighteen women with high-grade cervical or vulvar intraepithelial neoplasia who were
positive for human papillomavirus (HPV) 16 and were HLA-A2 positive were treated with …

The immunology of human papillomavirus (HPV) infections has peculiar characteristics. The
long latency for cervical cancer development after primary viral infection suggests …

Immunotherapy is one of the most promising strategies for the treatment of cancer. Human
papillomavirus (HPV) is responsible for virtually all cases of cervical cancer. The main …

High-risk genotypes of the human papillomavirus (HPV), particularly HPV type 16, are found
in a distinct subset of head and neck squamous cell carcinomas (HNSCC). Thus, these HPV …

One of the critical steps in the progression to cervical cancer appears to be the
establishment of persistent human papillomavirus (HPV) infection. We have demonstrated …

Conjugation of multiple peptides by their N-termini is a promising technique to produce
branched multiantigenic vaccines. We established a double conjugation strategy that …

The E6 and E7 oncoproteins of the high-risk HPV type16 represent ideal targets for HPV
vaccine development, they being consistently expressed in cervical cancer lesions. Since …

Abstract 'High risk'genotypes of the human papillomavirus (HPV), particularly HPV type 16,
are the primary etiologic agent of cervical cancer. Thus, HPV-associated cervical …